DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20162127

Correlation between second trimester beta human chorionic gonadotropin levels and pregnancy outcome in high risk group

Praveen Sharma, Sunita Maheshwari, Shivani Barala

Abstract


Background: Current obstetric practice uses second trimester maternal serum levels of alpha fetoprotein, beta human chorionic gonadotropin (b hCG), unconjugated estradiol as a screening tool for fetal aneuploidy. Given the obvious role of placenta in determining the maternal serum levels of these hormones, we evaluate their role as predictors of placental dysfunction as manifested by pregnancy outcome.

Methods: This prospective study was done in department of obstetrics and gynecology, RNT Medical College, Udaipur, Rajasthan on 150 patients attending the antenatal OPD and those admitted between 16 to 20 weeks of pregnancy. Mid-trimester serum b hCG levels was obtained in these patients. They were followed up till delivery or abortion to see for development of any obstetrical complication.

Results: Out of 100 cases in study group, 17% cases had level of serum b hCG >2 MOM and 83% cases had < 2 MOM. Out of 50 cases in control group, 8% cases had level of serum b hCG >2 MOM and 92% cases had < 2 MOM. Out of 17 cases in study group with high level of serum b hCG, 82.35% and 0% out of 4 cases in control group, developed PIH. Out of 17 cases with high level of b hCG in study group, 58.85% and 25% out of 4 cases in control group, developed IUGR.

Conclusions: Women with bad obstetric history and unexplained elevation of serum b hCG during second trimester are at an increased risk for PIH and IUGR.


Keywords


hCG, PIH, IUGR

Full Text:

PDF

References


Yaron Y, Cherry M, Kramer RL, O’Brien JE, Hallak M, Johnson MP, et al. Second trimester maternal serum marker screening: maternal serum alpha fetoprotein,  human chorionic gonadotropin, estriol and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999;181(4):968-74.

Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD. Implantation embryogenesis and placental development: Williams Obstetrics 22nd ed. Mc Graw hill Medical Publishing Division; 2001:70-2.

Vaillant P, David E, Constant I, Athmani B, Devuldur G, Fievet P, et al. Validity in nulliparas of increased p Human chorionic gonadotropin at mid-term for predicting pregnancy induced hypertension complicated with proteinuria and intrauterine growth retardation. Nephron. 1996;72:557-63.

Benn AP, Horne D, Briganti S, Rodis JF, Clive JM. Elevated second trimester maternal serum  hCG alone or in combination with elevated alpha fetoprotein. Obstet Gynecol. 1996;87(2):217-22.

Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M. The association between unexplained second trimester serum  hCG elevation and pregnancy complications. Obstet Gynecol. 1992;80(1):83-6.

Desai P, Rao S. Predictive value of raised mid-trimester β human chorionic gonadotropin in PIH. J Obstet and Gyn Ind. 2002;52(1):68-70.

Tanaka M, Natori M, Kohno H, Ishimoto H, Kobayashi T, Nozawa S. Fetal growth in patients with elevated maternal hCG levels. Obstet Gynecol. 1993;81(3):341-3.

Johnson P. Second trimester maternal serum β human chorionic gonadotrophin and pregnancy outcome. Br J Obstet and Gynaecol. 1999;106:598-600.

Wenstron KID, Owen J, Boots LR, Dubard MB. Elevated 2nd trimester human gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol. 1994;171(4):1038-41.